薬学部

Pharmacology, Toxicology and Pharmaceutical Science

1. Mouse 100%
2. Malignant Neoplasm 63%
3. Pharmacokinetics 57%
4. Neoplasm 45%
5. Adverse Event 44%
6. Liver Cell Carcinoma 41%
7. Vancomycin 38%
8. Disease 38%
9. Inflammation 30%
10. Fullerene Derivative 28%
11. Cytotoxicity 27%
12. microRNA 27%
13. ABCG2 26%
14. Clinical Trial 25%
15. Nanoparticle 25%
16. Helicobacter Pylori 24%
17. Therapeutic Drug Monitoring 23%
18. Retrospective Study 23%
19. Anticarcinogen 22%
20. Acetylcholine 22%
21. Chronic Kidney Failure 22%
22. Chemotherapy 20%
23. Cytokine 20%
24. Multiple Myeloma 19%
25. Diethylstilbestrol 19%
26. Adverse Drug Reaction 19%
27. Breast Cancer 19%
28. Anti-Inflammatory Drug 19%
29. Intestine Flora 19%
30. Transcription Factor Nrf2 19%
31. Drug Discovery 18%
32. Carbon Monoxide 17%
33. Nitric Oxide 17%
34. CYP3A4 17%
35. Cytochrome P450 17%
36. Interferon 16%
37. Infection 16%
38. High Performance Liquid Chromatography 16%
39. Liposome 16%
40. Chinese Hamster 16%
41. Antioxidant 15%
42. Biological Marker 15%
43. Tumor Necrosis Factor 15%
44. Reactive Oxygen Metabolite 14%
45. Observational Study 14%
46. Drug Development 14%
47. Rheumatoid Arthritis 14%
48. Rat Model 14%
49. P-Glycoprotein 14%
50. Non Small Cell Lung Cancer 14%
51. Combination Therapy 14%
52. Cohort Study 13%
53. Symptom 13%
54. Superoxide Dismutase 13%
55. Therapeutic Effect 13%
56. Acute Kidney Failure 13%
57. Gefitinib 13%
58. Linezolid 13%
59. Polypeptide 12%
60. Nicotinic Receptor 12%
61. Doxorubicin 12%
62. Hepatotoxicity 12%
63. Indometacin 12%
64. Chronic Hepatitis C 12%
65. Receptor 12%
66. Acetic Acid Derivative 12%
67. Nausea and Vomiting 11%
68. Pharmacodynamics 11%
69. Nonalcoholic Fatty Liver 11%
70. Muscle Atrophy 11%
71. Thalidomide 11%
72. Prodrug 11%
73. Epidermal Growth Factor Receptor 11%
74. Glycosphingolipid 11%
75. Dyspepsia 11%
76. Methemoglobin 11%
77. Antibiotics 11%
78. Chronic Myeloid Leukemia 11%
79. Clarithromycin 11%
80. Nephrotoxicity 11%
81. Mouse Model 11%
82. Monoclonal Antibody 11%
83. CYP2C19 11%
84. Antihypertensive Agent 11%
85. Butyrate 11%
86. Tablet 10%
87. Cisplatin 10%
88. Minimum Inhibitory Concentration 10%
89. Flavonoid 10%
90. Hydrogen Sulfide 9%
91. Human Serum Albumin 9%
92. Drug Resistance 9%
93. Daptomycin 9%
94. Metronidazole 9%
95. Voriconazole 9%
96. Amino Acid 9%
97. Leporidae 9%
98. Antiinfective Agent 9%
99. Pharmacotherapy 9%
100. Bioavailability 9%

Keyphrases

1. Japan 22%
2. Vancomycin 19%
3. Confidence Interval 17%
4. Acetylcholine 14%
5. Glycosphingolipids 12%
6. Multicenter Retrospective Study 12%
7. Risk Factors 12%
8. Nausea 11%
9. Vomiting 11%
10. Interferon-α (IFN-α) 11%
11. Odds Ratio 11%
12. Chinese Hamster V79 Cells 10%
13. Therapeutic Drug Monitoring 9%
14. Pharmacokinetics 9%
15. Area under the Concentration-time Curve 9%
16. Optically Active 9%
17. Cytotoxicity 9%
18. Meta-analysis 9%
19. Human Hepatoma Cells 9%
20. Immunological Activity 8%
21. Systematic Meta-analysis 8%
22. Inhibitory Effect 8%
23. MicroRNA 8%
24. Voriconazole 8%
25. Helicobacter Pylori Eradication 8%
26. Carboplatin 8%
27. Diethylstilbestrol 7%
28. Induced Apoptosis 7%
29. Apoptosis 7%
30. Multiple Myeloma 7%
31. Janus Kinase 2 (JAK2) 7%
32. Chronic Kidney Disease 7%
33. JAK2V617F 7%
34. Focal Adhesion Kinase 7%
35. D-galactose (D-gal) 7%
36. Structural Features 7%
37. Nephrotoxicity 7%
38. Nuclear Magnetic Resonance 7%
39. Propensity Score Analysis 7%
40. Monotherapy 6%
41. Chronic Myeloid Leukemia 6%
42. Breast Cancer Resistance Protein 6%
43. Nicotinic Acetylcholine Receptor (nAChR) 6%
44. Myeloma Cells 6%
45. Olanzapine 6%
46. Trough Concentration 6%
47. Phosphorylation 6%
48. Chemotherapy 6%
49. Daptomycin 6%
50. Nivolumab 6%
51. Liquid Scintillation Counting 6%
52. Microtubules 6%
53. Polysaccharide 6%
54. Butyrate 6%
55. Adverse Effects 6%
56. Clinical Trials 6%
57. Phorbol 12-myristate 13-acetate 6%
58. Thermoresponsive Polymer 5%
59. Japanese Patients 5%
60. T Cells 5%
61. Clarithromycin 5%
62. Muscarinic Acetylcholine Receptor 5%
63. Acute Kidney Injury 5%
64. Tumor 5%
65. Methylation Analysis 5%
66. Functional Dyspepsia 5%
67. Treatment Efficacy 5%
68. Logistic Regression Analysis 5%
69. Plasma Concentration 5%
70. Acidic Polysaccharide 5%
71. Fullerene Derivatives 5%
72. Theophylline 5%
73. Liver Cirrhosis 5%
74. Cytochrome P450 (CYP450) 5%
75. Poly(N-isopropylacrylamide) (PNIPAM) 5%
76. Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 5%
77. Signaling Pathway 5%
78. IRF1 5%
79. Glycolipids 5%
80. Alcohol 5%
81. Rheumatoid Arthritis 5%
82. Enantiomerically Pure 5%
83. HL-60 Cells 5%
84. M Cells 5%
85. Circulating microRNA 5%
86. Questionnaire Survey 5%
87. Linezolid 5%
88. Drug Development 5%
89. Epidermal Cells 5%